Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.69 USD | +0.81% | +2.70% | -36.83% |
Apr. 25 | Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained | MT |
Apr. 25 | Transcript : Sage Therapeutics, Inc., Q1 2024 Earnings Call, Apr 25, 2024 |
Business Summary
Number of employees: 487
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Medicines
100.0
%
| 8 | 100.0 % | 86 | 100.0 % | +1,024.84% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 8 | 100.0 % | 86 | 100.0 % | +1,024.84% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Barry Greene
CEO | Chief Executive Officer | 60 | 20-09-30 |
Steven Paul
FOU | Founder | 73 | 10-04-15 |
Kimi Iguchi
DFI | Director of Finance/CFO | 61 | 13-02-28 |
Mike Quirk
CTO | Chief Tech/Sci/R&D Officer | - | 13-12-31 |
Laura Gault
CTO | Chief Tech/Sci/R&D Officer | - | 22-10-30 |
Matt Lasmanis
CTO | Chief Tech/Sci/R&D Officer | - | 20-10-31 |
Amy Schacterle
COO | Chief Operating Officer | - | 15-02-12 |
Jeff Jonas
BRD | Director/Board Member | 71 | 13-08-13 |
Tammy J. Phinney
LAW | General Counsel | - | 20-07-31 |
Vanessa Procter
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jeff Jonas
BRD | Director/Board Member | 71 | 13-08-13 |
Steven Paul
FOU | Founder | 73 | 10-04-15 |
Barry Greene
CEO | Chief Executive Officer | 60 | 20-09-30 |
Jim Frates
BRD | Director/Board Member | 56 | 14-04-30 |
Michael Cola
BRD | Director/Board Member | 64 | 14-09-10 |
Geno Germano
CHM | Chairman | 63 | 16-07-18 |
Director/Board Member | 67 | 19-01-22 | |
Director/Board Member | 62 | 19-01-22 | |
Jessica Federer
BRD | Director/Board Member | - | 23-03-14 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 60,185,064 | 52,601,761 ( 87.40 %) | 3,033 ( 0.005039 %) | 87.40 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.83% | 824M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+0.82% | 22.15B | |
-17.37% | 21.02B | |
-8.00% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- SAGE Stock
- Company Sage Therapeutics, Inc.